Crysvita® (burosumab-twza)
| Full Name | Crysvita® (burosumab-twza) |
| Drug | Crysvita |
| Manufacturer | Kyowa Kirin North America |
| Route of Administration | Subcutaneous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older |
| Disease | Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH) |
| Therapeutic Area | Endocrinology & Bone Specialty |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-7614 |
| Fax Number | 877-793-4897 |
| Product Website | crysvitahcp.com |